참고문헌
- Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392;245-252, 1998 https://doi.org/10.1038/32588
- Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18;767-811, 2000 https://doi.org/10.1146/annurev.immunol.18.1.767
- Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90;1920-1926, 1997
- Nouri-Shirazi M, Banchereau J, Fay J, Palucka K: Dendritic cell based tumor vaccines. Immunol Letter 74;5-10, 2000 https://doi.org/10.1016/S0165-2478(00)00243-1
- Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53;240-248, 2004 https://doi.org/10.1007/s00262-003-0468-6
- Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101; 977-982, 2003 https://doi.org/10.1182/blood-2002-04-1273
- Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15; 138-147, 2003 https://doi.org/10.1016/S0952-7915(03)00015-3
- Kim A, Kim KD, Choi SC, Jeong MJ, Lee HG, Choe YK, Paik SG, Lim JS: IL-12 production and subsequent natural killer cell activation by necrotic tumor cell-loaded dendritic cells in therapeutic vaccinations. Immune Network 3;188-200, 2003 https://doi.org/10.4110/in.2003.3.3.188
- Moore MW, Carbone FR, Bevan MJ: Introduction of solubleprotein into the class-I pathway of antigen processing and presentation. Cell 54;777-785, 1988 https://doi.org/10.1016/S0092-8674(88)91043-4
- Karttunen J, Sanderson S, Shastri N: Detection of rare antigenpresenting cells by the LacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89;6020-6024, 1992
- Shen Z, Renznikoff G, Dranoff G, Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158;2723-2730, 1997
- Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J Exp Med 176; 1693-1702, 1992 https://doi.org/10.1084/jem.176.6.1693
- Shastri N, Gonzalez F: Endogenous generation and presentation of the ovalbumin peptide/k(b) complex to T-cells. J Immunol 150;2724-2736, 1993
- Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS: Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Exp Mol Med 36;428-443, 2004 https://doi.org/10.1038/emm.2004.55
- Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156;2918-2926, 1996
-
De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K: Retrovirally transduced bone marrow-derived dendritic cells require
$CD4^+$ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162; 144-151, 1999 - Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10;281-287, 1999 https://doi.org/10.1016/S1074-7613(00)80028-X
- Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C: Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27;280-288, 1997
- Shen Z, Reznikoff G, Dranoff G, Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158;2723-2730, 1997
- Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182;389-400, 1995 https://doi.org/10.1084/jem.182.2.389
- Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1;362-368, 1999 https://doi.org/10.1038/14058
- Okada N, Tsujino M, Hagiwara Y, Tada A, Tamura Y, Mori K, Saito T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A: Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 84;1564-1570, 2001 https://doi.org/10.1054/bjoc.2001.1801
- Galea-Lauri J, Wells J, Darling D, Harrison P, Farzaneh F: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53;963-977, 2004
- Eriksson K, Sun JB, Nordstrom I, Fredriksson M, Lindblad M, Li BL, Holmgren J: Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor. Eur J Immunol 34;1272-1281, 2004 https://doi.org/10.1002/eji.200324368
- Kim KW, Kim SH, Jang JH, Lee EY, Park SW, Um JH, Lee YJ, Lee CH, Yoon S, Seo SY, Jeong MH, Lee ST, Chung BS, Kang CD: Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. Cancer Immunol Immunother 53;315-522, 2004 https://doi.org/10.1007/s00262-003-0448-x
- Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20;2287-2295, 2002 https://doi.org/10.1016/S0264-410X(02)00103-2
- Nakanishi T, Hayashi A, Kunisawa J, Tsutsumi Y, Tanaka K, Yashiro-Ohtani Y, Nakanishi M, Fujiwara H, Hamaoka T, Mayumi T: Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol 30;1740-1747, 2000 https://doi.org/10.1002/1521-4141(200006)30:6<1740::AID-IMMU1740>3.0.CO;2-U